Article Sidebar
Published:
May 27, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of Alisma plantago-aquatica Linn extract on hyperprolactinemia in rats
Abstract
Purpose: To investigate the anti-hyperprolactinemia effect and mechanism of action of of Alisma plantago-aquatica Linn. extract (APLE) in rats.
Methods: The hyperprolactinemia (hyperPRL) model of rats was established by intraperitoneal (i.p.) metoclopramide (200 mg/kg daily) for 10 days. Sixty rats were divided into six groups (n = 10 each): normal group), hyperPRL control group, hyperPRL plus 0.6 mg/kg bromocriptine (as a positive control) group, and hyperPRL plus high (14.4 g/kg), medium (7.2 g/kg), or low (3.6 g/kg) dose of APLE. Bromocriptine or vehicle control was administered to the rats daily for 30 days, and the hypothalamus dopamine D2 receptor, protein kinase A (PKA), and cyclic adenosine monophosphate (cAMP) levels were investigated by Western blot.
Results: Compared with the normal rats, hypothalamus dopamine D2 receptor protein expression was significantly lower in hyperPRL rats (p < 0.01), but was changed significantly after 30-day doses (various) of APLE administration (3.6 g/kg, p < 0.05; 7.2 and 14.4 g/kg, p < 0.01). Compared with the control rats, hypothalamus PKA and cAMP levels were significantly higher in hyperPRL rats (p < 0.01). These increases in PKA and cAMP were significantly attenuated by 30-day of bromocriptine treatment or various doses of APLE (p < 0.01).
Conclusion: The anti-hyperPRL activity of APLE is confirmed from the findings of this study Thus, the plant can potentially be developed into a new anti-hyperprolactinemia drug.
